Tiagabine (Gabitril, Cephalon) labeling change to warn of seizure risk associated with the drug when used off-label to treat patients without epilepsy.
Rosuvastatin (Crestor, AstraZeneca) labeling change to warn that rhabdomyolysis may occur as a result of its use, especially in patients taking cyclosporine, in North Americans of Asian descent, and those with severe renal deficiency. A warning of jaundice was also added.
Anagrelide (Angrylin; Mallinckrodt, Roberts) labeling change regarding contraindications including its use in patients with severe hepatic impairment. Dosage reduction recommended in patients with moderate hepatic impairment and monitoring for cardiovascular effects.
Darbepoetin alfa (Aranesp, Amgen) labeling change to warn kidney dialysis and cancer patients that studies on similar drugs showed that higher doses can cause blood clots and death.
Email this article to a friend. Log on to www.geri.com Always on call.
COPYRIGHT 2005 Advanstar Communications, Inc.
COPYRIGHT 2005 Gale Group
Home
A
Oxytetracycline
